Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) remains a challenging malignancy with limited therapeutic options.
• Microtubule-stabilizing agents, like Utidelone (UTD1), have shown antitumor activity in solid tumors, but their efficacy in PDAC is not well-established.

Purpose of the Study:

• To investigate the therapeutic potential of Utidelone (UTD1) as a single agent and in combination with gemcitabine (GEM) for pancreatic ductal adenocarcinoma (PDAC).
• To elucidate the mechanisms underlying the combined efficacy of UTD1 and GEM, focusing on cell death induction and immune modulation.

Main Methods:

• In vitro studies included CCK8, colony formation, apoptosis, and cell cycle assays.
• In vivo studies utilized both xenograft and immunocompetent KPC mouse models.
• Immunophenotypic analysis assessed T cell infiltration and PD-L1 expression.

Main Results:

• Utidelone (UTD1) demonstrated dose-dependent suppression of PDAC cell proliferation, induction of apoptosis, and G2/M cell cycle arrest.
• The combination of UTD1 and gemcitabine (GEM) significantly enhanced antitumor efficacy in both in vitro and in vivo models.
• UTD1 + GEM treatment increased markers of immunogenic cell death (ICD), promoted CD4+/CD8+ T cell infiltration, and upregulated PD-L1 expression in KPC models, leading to improved survival and reduced tumor burden.

Conclusions:

• Utidelone (UTD1) exhibits significant antitumor activity in PDAC models, potentially by triggering immunogenic cell death (ICD).
• The combination of UTD1 and gemcitabine (GEM) offers enhanced therapeutic benefits for PDAC by potentiating ICD and modulating the tumor immune microenvironment.
• UTD1 represents a promising therapeutic strategy for PDAC, particularly in combination with chemotherapy, warranting further clinical investigation.